Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03633058 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
A Phase 2 study, sponsored by Rett Syndrome Research Trust.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03633058 is a Phase 2 study that has completed, run by Rett Syndrome Research Trust. The registered enrollment target is 23 participants.
The verdict
NCT03633058, a Phase 2 study, has completed, sponsored by Rett Syndrome Research Trust.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This 2 cohort, sequential, ascending dose study will assess the safety, tolerability and efficacy of oral ketamine dosed in a single 5-day BID regimen in addition to placebo, in a 4-week cross-over design in patients with Rett Syndrome. Approximately 12 patients per cohort are anticipated to participate for approximately 8-10 weeks at approximately 7 US study centers.
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-03-12 |
| Est. Completion | 2021-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03633058
The ClinicalTrials.gov registry entry for NCT03633058 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rett Syndrome Research Trust, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT03633058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03633058 about?
NCT03633058 is a clinical study titled "A Study to Evaluate Ketamine for the Treatment of Rett Syndrome". This 2 cohort, sequential, ascending dose study will assess the safety, tolerability and efficacy of oral ketamine dosed in a single 5-day BID regimen in addition to placebo, in a 4-week cross-over design in patients with Rett Syndrome. Approximately 12 patients per cohort are anticipated to partici...
What is the current status of trial NCT03633058?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2019-03-12. Estimated completion is 2021-11-22.
What interventions are being tested in trial NCT03633058?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT03633058?
This trial is sponsored by Rett Syndrome Research Trust, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.